Ibudilast (AV-411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The treatment of neuropathic pain is a major unresolved medical challenge. Present pharmacotherapies only have modest efficacy and numerous side effects. The use of opioid analgesics is additionally coupled with dependence and withdrawal syndromes. Ibudilast (AV-411) is a non-selective phosphodiesterase inhibitor that is also known to suppress glial cell activation. It has been used clinically for other indications with a good safety profile. As glial cell activation is considered to crucially contribute to neuropathic pain as well as opioid dependence and withdrawal, the authors conceived that ibudilast may be useful for treating these conditions. Preclinical data indicate that ibudilast crosses the blood-brain barrier, is well tolerated, is active on oral administration, reduces glial activation and attenuates pain symptoms in diverse rat models of neuropathic pain. In addition, it enhances acute morphine analgesia and attenuates morphine tolerance and withdrawal. Thus ibudilast may improve opioid efficacy and is a promising therapeutic candidate for neuropathic pain, with a novel mechanism of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
Bennett, G. J., & Xie, Y.-K. (1988) · Pain · doi:10.1016/0304-3959(88)90209-6 · Cited by 5,376
Neuronal plasticity: Increasing the gain in pain
Woolf, C. J., & Salter, M. W. (2000) · Science · doi:10.1126/science.288.5472.1765 · Cited by 3,781 · cited 1×
“, in the spinal cord dorsal horn) become sensitized (hyperexcitable), signaling pain despite the absence of painful stimuli [3-5] .”
BackgroundHo Kim, S., & Mo Chung, J. (1992) · Pain · doi:10.1016/0304-3959(92)90041-9 · Cited by 3,069 · cited 1×
“Specifically, it was tested whether ibudilast could attenuate low-threshold mechanical allodynia induced in rats by peripheral nerve injury (chronic constriction injury [CCI] of the sciatic nerve) [52] , spinal nerve ligation [53] and the chemotherapy drug paclitaxel [54] .”
BackgroundThe induction of pain: an integrative review
Millan, M. J. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00048-3 · Cited by 1,774 · cited 1×
“, in the spinal cord dorsal horn) become sensitized (hyperexcitable), signaling pain despite the absence of painful stimuli [3-5] .”
BackgroundOpioids in chronic non-cancer pain: systematic review of efficacy and safety
Kalso, E., Edwards, J. E., Moore, A. R., & McQuay, H. J. (2004) · Pain · doi:10.1016/j.pain.2004.09.019 · Cited by 1,216
Role of the Immune system in chronic pain
Marchand, F., Perretti, M., & McMahon, S. B. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1700 · Cited by 1,098
Ledeboer, A., Sloane, E. M., Milligan, E. D., Frank, M. G., Mahony, J. H., Maier, S. F., & Watkins, L. R. (2005) · Pain · doi:10.1016/j.pain.2005.02.009 · Cited by 677
Self-citationA painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel
Polomano, R. C., Mannes, A. J., Clark, U. S., & Bennett, G. J. (2001) · Pain · doi:10.1016/s0304-3959(01)00363-3 · Cited by 476
The involvement of glial cells in the development of morphine tolerance
Song, P., & Zhao, Z.-Q. (2001) · Neuroscience Research · doi:10.1016/s0168-0102(00)00226-1 · Cited by 445
Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442 · cited 1×
“Indeed, the prototypical PDE4 inhibitor rolipram exhibits efficacy in animal models of Alzheimer’s disease [87] , multiple sclerosis (MS) [88] and spinal cord injury [89] .”
Background
Cited by
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
TNF-α and neuropathic pain - a review
Leung, L., & Cahill, C. M. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-27 · Cited by 630
Importance of glial activation in neuropathic pain
Mika, J., Zychowska, M., Popiolek-Barczyk, K., Rojewska, E., & Przewlocka, B. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.072 · Cited by 460
Inflammogenesis of Secondary Spinal Cord Injury
Anwar, M. A., Al Shehabi, T. S., & Eid, A. H. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00098 · Cited by 440
Watkins, L. R., Hutchinson, M. R., Rice, K. C., & Maier, S. F. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.002 · Cited by 438
Self-citation
Metadata
- Authors
- Ledeboer, A., Hutchinson, M. R., Watkins, L. R., & Johnson, K. W.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2007-06-26
- Volume
- 16
- Issue
- 7
- Pages
- 935-950
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1948711363
- Cited by
- 153
- References
- 12
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ibudilast (AV-411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. https://app.cochat.ai/papers/10.1517/13543784.16.7.935
- The paper
- Ledeboer, A., Hutchinson, M. R., Watkins, L. R., & Johnson, K. W. (2007). Ibudilast (AV-411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.16.7.935
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.